Thalidomide in the treatment of leprosy
Leprosy is a chronic infection of the skin and nerves caused by Mycobacterium leprae. Erythema nodosum leprosum (ENL) is a reactive state in lepromatous leprosy. Thalidomide has been used to treat ENL since the 1960s. One of its mechanisms of action is anti-inflammatory through selective inhibition...
Gespeichert in:
| Veröffentlicht in: | Microbes and Infection 2002-09, Vol.4 (11), p.1193-1202 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1202 |
|---|---|
| container_issue | 11 |
| container_start_page | 1193 |
| container_title | Microbes and Infection |
| container_volume | 4 |
| creator | Teo, Steve K. Resztak, Ken E. Scheffler, Michael A. Kook, Karin A. Zeldis, Jerry B. Stirling, David I. Thomas, Steve D. |
| description | Leprosy is a chronic infection of the skin and nerves caused by
Mycobacterium leprae. Erythema nodosum leprosum (ENL) is a reactive state in lepromatous leprosy. Thalidomide has been used to treat ENL since the 1960s. One of its mechanisms of action is anti-inflammatory through selective inhibition of the pro-inflammatory cytokine TNF-α produced by monocytes. |
| doi_str_mv | 10.1016/S1286-4579(02)01645-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_18533297</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1286457902016453</els_id><sourcerecordid>18533297</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-e28ad6560afd3dad47d8492a0ac9065d031f38d6c6260c8cd629320529e58d13</originalsourceid><addsrcrecordid>eNqFkElLAzEUgIMoVqs_QZmL22E0-0xOIsUNCh7swVuIyRsamaUmU6H_3rQd6dHTezy-t30InRF8SzCRd--EljLnolDXmN6kChc520NHpJAqLwj_2E_5HzJCxzF-YUxEIfkhGhHKJFEUH6Gr2dzU3nWNd5D5NuvnkPUBTN9A22ddldWwCF1cnaCDytQRToc4RrOnx9nkJZ--Pb9OHqa55bzoc6ClcVJIbCrHnHG8cCVX1GBjFZbCYUYqVjppJZXYltZJqhjFgioQpSNsjC63Y9PS7yXEXjc-Wqhr00K3jJqUgjGqigSKLWjTdTFApRfBNyasNMF6LUhvBOn19xpTvRGkWeo7HxYsPxtwu67BSAIuBsBEa-oqmNb6uOOYokpJmrj7LQfJxo-HoKP10FpwPoDttev8P6f8AqFogHM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18533297</pqid></control><display><type>article</type><title>Thalidomide in the treatment of leprosy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Teo, Steve K. ; Resztak, Ken E. ; Scheffler, Michael A. ; Kook, Karin A. ; Zeldis, Jerry B. ; Stirling, David I. ; Thomas, Steve D.</creator><creatorcontrib>Teo, Steve K. ; Resztak, Ken E. ; Scheffler, Michael A. ; Kook, Karin A. ; Zeldis, Jerry B. ; Stirling, David I. ; Thomas, Steve D.</creatorcontrib><description>Leprosy is a chronic infection of the skin and nerves caused by
Mycobacterium leprae. Erythema nodosum leprosum (ENL) is a reactive state in lepromatous leprosy. Thalidomide has been used to treat ENL since the 1960s. One of its mechanisms of action is anti-inflammatory through selective inhibition of the pro-inflammatory cytokine TNF-α produced by monocytes.</description><identifier>ISSN: 1286-4579</identifier><identifier>EISSN: 1769-714X</identifier><identifier>DOI: 10.1016/S1286-4579(02)01645-3</identifier><identifier>PMID: 12361920</identifier><language>eng</language><publisher>Lausanne: Elsevier SAS</publisher><subject>Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacterial diseases ; Biological and medical sciences ; Drug Therapy, Combination ; Erythema Nodosum - drug therapy ; Erythema Nodosum - pathology ; Erythema nodosum leprosum ; Human bacterial diseases ; Humans ; Incidence ; Infectious diseases ; Leprostatic Agents - therapeutic use ; Leprosy ; Leprosy - drug therapy ; Leprosy - pathology ; Leprosy - transmission ; Leprosy, Lepromatous - drug therapy ; Leprosy, Lepromatous - pathology ; Medical sciences ; Models, Molecular ; Mycobacterium leprae - pathogenicity ; Pharmacology. Drug treatments ; Thalidomide ; Thalidomide - adverse effects ; Thalidomide - pharmacokinetics ; Thalidomide - pharmacology ; Thalidomide - therapeutic use ; Tropical bacterial diseases ; Tumor Necrosis Factor-alpha - metabolism ; Type 2 reaction</subject><ispartof>Microbes and Infection, 2002-09, Vol.4 (11), p.1193-1202</ispartof><rights>2002 Éditions scientifiques et médicales Elsevier SAS</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-e28ad6560afd3dad47d8492a0ac9065d031f38d6c6260c8cd629320529e58d13</citedby><cites>FETCH-LOGICAL-c447t-e28ad6560afd3dad47d8492a0ac9065d031f38d6c6260c8cd629320529e58d13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1286457902016453$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>313,314,776,780,788,3537,27899,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13929962$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12361920$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Teo, Steve K.</creatorcontrib><creatorcontrib>Resztak, Ken E.</creatorcontrib><creatorcontrib>Scheffler, Michael A.</creatorcontrib><creatorcontrib>Kook, Karin A.</creatorcontrib><creatorcontrib>Zeldis, Jerry B.</creatorcontrib><creatorcontrib>Stirling, David I.</creatorcontrib><creatorcontrib>Thomas, Steve D.</creatorcontrib><title>Thalidomide in the treatment of leprosy</title><title>Microbes and Infection</title><addtitle>Microbes Infect</addtitle><description>Leprosy is a chronic infection of the skin and nerves caused by
Mycobacterium leprae. Erythema nodosum leprosum (ENL) is a reactive state in lepromatous leprosy. Thalidomide has been used to treat ENL since the 1960s. One of its mechanisms of action is anti-inflammatory through selective inhibition of the pro-inflammatory cytokine TNF-α produced by monocytes.</description><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>Drug Therapy, Combination</subject><subject>Erythema Nodosum - drug therapy</subject><subject>Erythema Nodosum - pathology</subject><subject>Erythema nodosum leprosum</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infectious diseases</subject><subject>Leprostatic Agents - therapeutic use</subject><subject>Leprosy</subject><subject>Leprosy - drug therapy</subject><subject>Leprosy - pathology</subject><subject>Leprosy - transmission</subject><subject>Leprosy, Lepromatous - drug therapy</subject><subject>Leprosy, Lepromatous - pathology</subject><subject>Medical sciences</subject><subject>Models, Molecular</subject><subject>Mycobacterium leprae - pathogenicity</subject><subject>Pharmacology. Drug treatments</subject><subject>Thalidomide</subject><subject>Thalidomide - adverse effects</subject><subject>Thalidomide - pharmacokinetics</subject><subject>Thalidomide - pharmacology</subject><subject>Thalidomide - therapeutic use</subject><subject>Tropical bacterial diseases</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><subject>Type 2 reaction</subject><issn>1286-4579</issn><issn>1769-714X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkElLAzEUgIMoVqs_QZmL22E0-0xOIsUNCh7swVuIyRsamaUmU6H_3rQd6dHTezy-t30InRF8SzCRd--EljLnolDXmN6kChc520NHpJAqLwj_2E_5HzJCxzF-YUxEIfkhGhHKJFEUH6Gr2dzU3nWNd5D5NuvnkPUBTN9A22ddldWwCF1cnaCDytQRToc4RrOnx9nkJZ--Pb9OHqa55bzoc6ClcVJIbCrHnHG8cCVX1GBjFZbCYUYqVjppJZXYltZJqhjFgioQpSNsjC63Y9PS7yXEXjc-Wqhr00K3jJqUgjGqigSKLWjTdTFApRfBNyasNMF6LUhvBOn19xpTvRGkWeo7HxYsPxtwu67BSAIuBsBEa-oqmNb6uOOYokpJmrj7LQfJxo-HoKP10FpwPoDttev8P6f8AqFogHM</recordid><startdate>20020901</startdate><enddate>20020901</enddate><creator>Teo, Steve K.</creator><creator>Resztak, Ken E.</creator><creator>Scheffler, Michael A.</creator><creator>Kook, Karin A.</creator><creator>Zeldis, Jerry B.</creator><creator>Stirling, David I.</creator><creator>Thomas, Steve D.</creator><general>Elsevier SAS</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>20020901</creationdate><title>Thalidomide in the treatment of leprosy</title><author>Teo, Steve K. ; Resztak, Ken E. ; Scheffler, Michael A. ; Kook, Karin A. ; Zeldis, Jerry B. ; Stirling, David I. ; Thomas, Steve D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-e28ad6560afd3dad47d8492a0ac9065d031f38d6c6260c8cd629320529e58d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>Drug Therapy, Combination</topic><topic>Erythema Nodosum - drug therapy</topic><topic>Erythema Nodosum - pathology</topic><topic>Erythema nodosum leprosum</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infectious diseases</topic><topic>Leprostatic Agents - therapeutic use</topic><topic>Leprosy</topic><topic>Leprosy - drug therapy</topic><topic>Leprosy - pathology</topic><topic>Leprosy - transmission</topic><topic>Leprosy, Lepromatous - drug therapy</topic><topic>Leprosy, Lepromatous - pathology</topic><topic>Medical sciences</topic><topic>Models, Molecular</topic><topic>Mycobacterium leprae - pathogenicity</topic><topic>Pharmacology. Drug treatments</topic><topic>Thalidomide</topic><topic>Thalidomide - adverse effects</topic><topic>Thalidomide - pharmacokinetics</topic><topic>Thalidomide - pharmacology</topic><topic>Thalidomide - therapeutic use</topic><topic>Tropical bacterial diseases</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><topic>Type 2 reaction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Teo, Steve K.</creatorcontrib><creatorcontrib>Resztak, Ken E.</creatorcontrib><creatorcontrib>Scheffler, Michael A.</creatorcontrib><creatorcontrib>Kook, Karin A.</creatorcontrib><creatorcontrib>Zeldis, Jerry B.</creatorcontrib><creatorcontrib>Stirling, David I.</creatorcontrib><creatorcontrib>Thomas, Steve D.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Microbes and Infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Teo, Steve K.</au><au>Resztak, Ken E.</au><au>Scheffler, Michael A.</au><au>Kook, Karin A.</au><au>Zeldis, Jerry B.</au><au>Stirling, David I.</au><au>Thomas, Steve D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thalidomide in the treatment of leprosy</atitle><jtitle>Microbes and Infection</jtitle><addtitle>Microbes Infect</addtitle><date>2002-09-01</date><risdate>2002</risdate><volume>4</volume><issue>11</issue><spage>1193</spage><epage>1202</epage><pages>1193-1202</pages><issn>1286-4579</issn><eissn>1769-714X</eissn><abstract>Leprosy is a chronic infection of the skin and nerves caused by
Mycobacterium leprae. Erythema nodosum leprosum (ENL) is a reactive state in lepromatous leprosy. Thalidomide has been used to treat ENL since the 1960s. One of its mechanisms of action is anti-inflammatory through selective inhibition of the pro-inflammatory cytokine TNF-α produced by monocytes.</abstract><cop>Lausanne</cop><cop>Amsterdam</cop><cop>Paris</cop><pub>Elsevier SAS</pub><pmid>12361920</pmid><doi>10.1016/S1286-4579(02)01645-3</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1286-4579 |
| ispartof | Microbes and Infection, 2002-09, Vol.4 (11), p.1193-1202 |
| issn | 1286-4579 1769-714X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_18533297 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Bacterial diseases Biological and medical sciences Drug Therapy, Combination Erythema Nodosum - drug therapy Erythema Nodosum - pathology Erythema nodosum leprosum Human bacterial diseases Humans Incidence Infectious diseases Leprostatic Agents - therapeutic use Leprosy Leprosy - drug therapy Leprosy - pathology Leprosy - transmission Leprosy, Lepromatous - drug therapy Leprosy, Lepromatous - pathology Medical sciences Models, Molecular Mycobacterium leprae - pathogenicity Pharmacology. Drug treatments Thalidomide Thalidomide - adverse effects Thalidomide - pharmacokinetics Thalidomide - pharmacology Thalidomide - therapeutic use Tropical bacterial diseases Tumor Necrosis Factor-alpha - metabolism Type 2 reaction |
| title | Thalidomide in the treatment of leprosy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T02%3A05%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thalidomide%20in%20the%20treatment%20of%20leprosy&rft.jtitle=Microbes%20and%20Infection&rft.au=Teo,%20Steve%20K.&rft.date=2002-09-01&rft.volume=4&rft.issue=11&rft.spage=1193&rft.epage=1202&rft.pages=1193-1202&rft.issn=1286-4579&rft.eissn=1769-714X&rft_id=info:doi/10.1016/S1286-4579(02)01645-3&rft_dat=%3Cproquest_cross%3E18533297%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18533297&rft_id=info:pmid/12361920&rft_els_id=S1286457902016453&rfr_iscdi=true |